Biotech giant AstraZeneca has completed its $1.1 billion acquisition of Icosavax, a Seattle-based spinout from the University of Washington’s Institute for Protein Design.
Seattle-based Icosavax, a spin-out from the University of Washington’s Institute for Protein Design, will be acquired by biotech giant AstraZeneca for up to $1.1 billion. The pending acquisition, announced Tuesday, values… Read More